An evaluation of asciminib for patients with chronic myeloid leukemia previously treated with ≥2 tyrosine kinase inhibitors

被引:4
作者
Garcia-Gutierrez, Valentin [1 ]
Carlos Hernandez-Boluda, Juan [2 ]
机构
[1] Univ Alcala, Hosp Univ Ramon y Cajal, Serv Hematol, IRYCIS, Madrid, Spain
[2] Univ Valencia, Hosp Clin Univ, Serv Hematol, INCLIVA, Valencia, Spain
关键词
Allosteric inhibition; asciminib; chronic myeloid leukemia; intolerance; resistance; STAMP inhibitor; tyrosine kinase inhibitors; ADVERSE EVENTS; PONATINIB; IMATINIB; BOSUTINIB; EFFICACY; TRIAL;
D O I
10.1080/17474086.2022.2080049
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: To date, five tyrosine kinase inhibitors (TKIs) are available for treating chronic myeloid leukemia (CML) patients in clinical practice. Despite this, a significant proportion of patients will ultimately develop failure to approved TKIs due to intolerance or resistance. Consequently, new treatment approaches are still required in this unmet clinical need. Asciminib, a first-in-class BCR:: ABL1 inhibitor Specifically Targeting the ABL Myristoyl Pocket (STAMP), has the potential to overcome resistance/intolerance to prior TKI treatment. Areas covered: This review will cover the mechanism of action, pharmacokinetic profile, and clinical data of asciminib based on available information from laboratory studies, clinical trials, and real-world evidence. Expert opinion: Recent approval of asciminib will require positioning of this drug in the treatment algorithm of CML patients failing initial TKI therapy. Available data support the lack of cross-intolerance of asciminib with other TKIs and its favorable cardiovascular toxicity profile. In addition, asciminib has demonstrated considerable efficacy in CML patients who have failed at least two TKIs, although preliminary data suggest that this efficacy may be lower in those previously exposed to ponatinib. The introduction of asciminib in clinical practice may represent an important step forward in the management of CML.
引用
收藏
页码:477 / 484
页数:8
相关论文
共 40 条
[11]   Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib [J].
Cortes, Jorge E. ;
Khoury, Hanna J. ;
Kantarjian, Hagop M. ;
Lipton, Jeff H. ;
Kim, Dong-Wook ;
Schafhausen, Philippe ;
Matczak, Ewa ;
Leip, Eric ;
Noonan, Kay ;
Bruemmendorf, Tim H. ;
Gambacorti-Passerini, Carlo .
AMERICAN JOURNAL OF HEMATOLOGY, 2016, 91 (12) :1206-1214
[12]  
Deininger Michael, 2008, J Natl Compr Canc Netw, V6 Suppl 2, pS11
[13]   Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE) [J].
Do, Young Rok ;
Kwak, Jae-Yong ;
Kim, Jeong A. ;
Kim, Hyeoung Joon ;
Chung, Joo Seop ;
Shin, Ho-Jin ;
Kim, Sung-Hyun ;
Bunworasate, Udomsak ;
Choi, Chul Won ;
Zang, Dae Young ;
Oh, Suk Joong ;
Jootar, Saengsuree ;
Reksodiputro, Ary Harryanto ;
Lee, Won Sik ;
Mun, Yeung-Chul ;
Kong, Jee Hyun ;
Caguioa, Priscilla B. ;
Kim, Hawk ;
Park, Jinny ;
Kim, Dong-Wook .
BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 (02) :303-312
[14]   Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients [J].
Dorer, David J. ;
Knickerbocker, Ronald K. ;
Baccarani, Michele ;
Cortes, Jorge E. ;
Hochhaus, Andreas ;
Talpaz, Moshe ;
Haluska, Frank G. .
LEUKEMIA RESEARCH, 2016, 48 :84-91
[15]   Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants [J].
Eide, Christopher A. ;
Zabriskie, Matthew S. ;
Stevens, Samantha L. Savage ;
Antelope, Orlando ;
Vellore, Nadeem A. ;
Than, Hein ;
Schultz, Anna Reister ;
Clair, Phillip ;
Bowler, Amber D. ;
Pomicter, Anthony D. ;
Yan, Dongqing ;
Senina, Anna, V ;
Qiang, Wang ;
Kelley, Todd W. ;
Szankasi, Philippe ;
Heinrich, Michael C. ;
Tyner, Jeffrey W. ;
Rea, Delphine ;
Cayuela, Jean-Michel ;
Kim, Dong-Wook ;
Tognon, Cristina E. ;
O'Hare, Thomas ;
Druker, Brian J. ;
Deininger, Michael W. .
CANCER CELL, 2019, 36 (04) :431-+
[16]   Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice [J].
Garcia-Gutierrez, Valentin ;
Luna, Alejandro ;
Alonso-Dominguez, Juan M. ;
Estrada, Natalia ;
Boque, Concepcion ;
Xicoy, Blanca ;
Giraldo, Pilar ;
Angona, Anna ;
Alvarez-Larran, Alberto ;
Sanchez-Guijo, Fermin ;
Ramirez, Maria Jose ;
Mora, Elvira ;
Velez, Patricia ;
Rosell, Ana ;
Colorado Araujo, Mercedes ;
Cuevas, Beatriz ;
Sagues, Miguel ;
Cortes, Montserrat ;
Encinas, Manuel Perez ;
Casado Montero, Luis Felipe ;
Moreno Vega, Melania ;
Serrano, Luis ;
Gomez, Valle ;
Garcia-Hernandez, Carmen ;
Lakhwani, Sunil ;
Paz Coll, Antonio ;
de Paz, Raquel ;
Suarez-Varela, Sara ;
Fernandez-Ruiz, Andres ;
Perez Lopez, Raul ;
Ortiz-Fernandez, Almudena ;
Jimenez-Velasco, Antonio ;
Steegmann-Olmedillas, Juan Luis ;
Hernandez-Boluda, Juan Carlos .
BLOOD CANCER JOURNAL, 2021, 11 (02)
[17]   Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety [J].
Garcia-Gutierrez, Valentin ;
Carlos Hernandez-Boluda, Juan .
FRONTIERS IN ONCOLOGY, 2019, 9
[18]   Pharmacokinetics of Asciminib in Individuals With Hepatic or Renal Impairment [J].
Hoch, Matthias ;
Sato, Masahiko ;
Zack, Julia ;
Quinlan, Michelle ;
Sengupta, Tirtha ;
Allepuz, Alex ;
Aimone, Paola ;
Hourcade-Potelleret, Florence .
JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 61 (11) :1454-1465
[19]   European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia [J].
Hochhaus, A. ;
Baccarani, M. ;
Silver, R. T. ;
Schiffer, C. ;
Apperley, J. F. ;
Cervantes, F. ;
Clark, R. E. ;
Cortes, J. E. ;
Deininger, M. W. ;
Guilhot, F. ;
Hjorth-Hansen, H. ;
Hughes, T. P. ;
Janssen, J. J. W. M. ;
Kantarjian, H. M. ;
Kim, D. W. ;
Larson, R. A. ;
Lipton, J. H. ;
Mahon, F. X. ;
Mayer, J. ;
Nicolini, F. ;
Niederwieser, D. ;
Pane, F. ;
Radich, J. P. ;
Rea, D. ;
Richter, J. ;
Rosti, G. ;
Rousselot, P. ;
Saglio, G. ;
Saussele, S. ;
Soverini, S. ;
Steegmann, J. L. ;
Turkina, A. ;
Zaritskey, A. ;
Hehlmann, R. .
LEUKEMIA, 2020, 34 (04) :966-984
[20]   Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].
Hochhaus, A. ;
Saussele, S. ;
Rosti, G. ;
Mahon, F. -X. ;
Janssen, J. J. W. M. ;
Hjorth-Hansen, H. ;
Richter, J. ;
Buske, C. .
ANNALS OF ONCOLOGY, 2017, 28 :41-51